Opendata, web and dolomites

SECRET SIGNED

Exploitation of the SECRETory pathway for cancer therapy to address European research

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 SECRET project word cloud

Explore the words cloud of the SECRET project. It provides you a very rough idea of what is the project "SECRET" about.

serve    translational    therapeutic    frequent    career    incomplete    metastasis    contributes    talented    cancers    purposes    bc    holds    tnbc    prognosis    infancy    promise    microenvironment    interdisciplinary    option    therapies    biology    drive    regulation    activation    metastases    negative    polarity    signaling    prone    train    evasion    selective    11    subgroup    countries    hyperproliferation    19    tumor    accounting    inspire    interrogate    regulated    motility    chemotherapy    academia    secretory    shaping    underpinning    deaths    stuttgart    dysregulated    broadly    university    strategies    aberrant    progression    altered    esrs    therapy    patients    hallmarks    death    treasure    suppression    applicable    intersectoral    triple    crc    coordinated    rates    resistance    diagnostic    secretome    presentation    15    secret    mutual    invasion    trove    training    colorectal    poor    approved    treatment    breast    platform    limited    industry    driver    medicine    secretion    cancer    proteins    beneficiaries    cell   

Project "SECRET" data sheet

The following table provides information about the project.

Coordinator
UNIVERSITAET STUTTGART 

Organization address
address: KEPLERSTRASSE 7
city: STUTTGART
postcode: 70174
website: www.uni-stuttgart.de

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Germany [DE]
 Total cost 3˙955˙339 €
 EC max contribution 3˙955˙339 € (100%)
 Programme 1. H2020-EU.1.3.1. (Fostering new skills by means of excellent initial training of researchers)
 Code Call H2020-MSCA-ITN-2019
 Funding Scheme MSCA-ITN-ETN
 Starting year 2019
 Duration (year-month-day) from 2019-10-01   to  2023-09-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    UNIVERSITAET STUTTGART DE (STUTTGART) coordinator 758˙365.00
2    UNIVERSITETET I OSLO NO (OSLO) participant 584˙684.00
3    STICHTING VUMC NL (AMSTERDAM) participant 531˙239.00
4    OSLO UNIVERSITETSSYKEHUS HF NO (OSLO) participant 292˙342.00
5    MEDIZINISCHE UNIVERSITAET WIEN AT (WIEN) participant 264˙207.00
6    TEL AVIV UNIVERSITY IL (TEL AVIV) participant 263˙500.00
7    CONSIGLIO NAZIONALE DELLE RICERCHE IT (ROMA) participant 261˙499.00
8    CHARLES RIVER DISCOVERY RESEARCH SERVICES GERMANY GMBH DE (FREIBURG) participant 252˙788.00
9    UNIVERSITAETSKLINIKUM FREIBURG DE (FREIBURG) participant 252˙788.00
10    ANAXOMICS BIOTECH SL ES (BARCELONA) participant 250˙904.00
11    PROTATOUANS - ETAIREIA EREYNAS VIOTECHNOLOGIAS MONOPROSOPI ETAIREIA PERIORISMENIS EYTHINIS EL (GLYFADA) participant 243˙017.00

Map

 Project objective

Breast and colorectal cancer (BC and CRC) are the most frequent cancers accounting for 19% of all deaths from cancer in Europe. In case of triple-negative BC (TNBC) targeted therapies are not available and non-selective chemotherapy is the only treatment option. Targeted therapy has been approved for the treatment of advanced CRC, but response rates are low and treatment is limited to a subgroup of patients. Also, TNBC and CRC patients are prone to develop metastases and have a poor prognosis underpinning the need for new targeted and broadly applicable therapeutic strategies. Tumor cell secretion contributes to hallmarks of cancer e.g. hyperproliferation, evasion of growth suppression, loss of cell polarity, activation of cell motility, invasion and metastasis, shaping of the tumor microenvironment through altered presentation of proteins and the secretome, and resistance to cell death. Dysregulated secretion is thus a driver of cancer progression and therefore holds promise as a general therapeutic target for the treatment of cancers. However, strategies to exploit the secretory pathway for therapeutic and diagnostic purposes are still in their infancy due to the incomplete understanding of how this pathway is regulated by aberrant signaling. The overall research objective of SECRET is to drive the understanding of the mutual regulation of the secretory pathway and signaling in cancer, which will serve as a platform to identify and interrogate novel diagnostic and therapeutic strategies. SECRET comprises 11 beneficiaries and 7 partner organizations from 9 countries. Coordinated by the University of Stuttgart, SECRET will train 15 talented ESRs in the field of translational cancer systems cell biology and systems medicine towards a career in industry or academia through a highly interdisciplinary and intersectoral research training programme and inspire them to exploit the SECRETory pathway as a treasure trove to design novel therapeutic strategies against cancer.

 Publications

year authors and title journal last update
List of publications.
2019 Olayioye, Noll, Hausser
Spatiotemporal Control of Intracellular Membrane Trafficking by Rho GTPases
published pages: 1478, ISSN: 2073-4409, DOI: 10.3390/cells8121478
Cells 8/12 2020-04-08

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "SECRET" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "SECRET" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.1.)

EAGRE (2020)

Eagre/Aegir: high-seas wave-impact modelling

Read More  

CORVOS (2019)

COmplement Regulation and Variations in Opportunistic infectionS

Read More  

SuperCol (2020)

SuperCol: Rational design of super-selective and responsive colloidal particles for biomedical applications

Read More